CM
ALNY icon

Crestline Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Crestline Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-10,814
Closed -$863K – 125
2017
Q2 		$863K Buy
+10,814
New +$691K 0.12% 93

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Crestline Management's ALNY Position: Q3 2017 in Review

Crestline Management sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2017, closing a stake of 10,814 shares — an estimated $863K sold.

Crestline Management first reported a position in ALNY in Q2 2017 and held it in 1 quarter. The position peaked at $863K in Q2 2017. 235 funds tracked by Wall St. Rank hold ALNY as of Q3 2017.

  • Crestline Management reported no remaining Alnylam Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Crestline Management sold 10,814 Alnylam Pharmaceuticals shares in Q3 2017, an estimated $863K.
  • Crestline Management first reported a position in Alnylam Pharmaceuticals in Q2 2017 and held it in 1 quarter.
  • Crestline Management's Alnylam Pharmaceuticals position peaked at $863K in Q2 2017.
  • 235 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2017.

Based on Crestline Management's 13F filing for Q3 2017, filed 14 Nov 2017.